Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28332220 | 0.81 | THRB (0.50) | THRBKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL11300864 | 0.74 | — | — | |
| SCHEMBL3063032 | 0.74 | KDM4E (0.35) | THRBKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL7263467 | 0.74 | THRB (0.32) | THRBKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL8016292 | 0.74 | TDP1 (0.40) | KMT2AMEN1TSHRALDH1A1HTT | |
| SCHEMBL15675893 | 0.74 | ALDH1A1 (0.32) | THRBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8364149 | 0.73 | CA5A (0.32) | THRBKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL1665864 | 0.73 | THRB (0.48) | THRBKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL600052 | 0.69 | THRB (0.56) | THRBKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL17474445 | 0.68 | CES2 (0.34) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589816-A | Electromagnetic shielding wave absorbing film and preparation method thereof | 驭奇材料科技常州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2018098342-A1 | N-ACETYLATED SIALIC ACIDS AND RELATED SIALOSIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-1160240-B1 | Guanylhydrazones for treating inflammatory conditions | CYTOKINE PHARMASCIENCES INC (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-0746312-B1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | PICOWER INST MED RES (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | BIANCHI MARINA (IT) | 2002-03-07 | — | — | US | disclosed |
| EP-1160240-A1 | Guanylhydrazones for treating inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6248787-B1 | REDUCING CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-06-19 | — | — | US | disclosed |
| US-6180676-B1 | THERAPY FOR CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-01-30 | — | — | US | disclosed |
| US-6022900-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-02-08 | — | — | US | disclosed |
| US-6008255-A | TREATING ENDOTOXIC SHOCK BY ADMINISTERING COMPOUNDS OF GIVEN FORMULA WHICH ARE AROMATICS SUBSTITUTED WITH MULTIPLE GUANYLHYDRAZONE MOIETIES, MORE PROPERLY TERMED AMIDINOHYDRAZONES (H2N-C(=NH)-NH-N=) | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0746312-A4 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | PICOWER INST MED RES (US) | 1999-05-26 | — | — | EP | disclosed |
| US-5859062-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASES MEDIATED BY TUMOR NECROSIS FACTOR | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854289-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-29 | — | — | US | disclosed |
| US-5849794-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-15 | — | — | US | disclosed |
| US-5753684-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-19 | — | — | US | disclosed |
| US-5750573-A | PREVENTING AND TREATING CACHEXIA, THE CLINICAL SYNDROME OF POOR NUTRITION AND BODILY WASTING ASSOCIATED WITH CANCER AND CHRONIC DISEASES; ARGINASE INHIBITORS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-12 | — | — | US | disclosed |
| US-5599984-A | AROMATIC AMIDINOHYDRAZONES AS INHIBITORS FOR THE UPTAKE OF ARGININE BY MACROPHAGES AND/OR ITS CONVERSION TO UREA; PREVENTION OF NITRIC OXIDE GENERATION; CACHEXIA; METABOLIC SYNDROMES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0746312-A1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995019767-A1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | ARG1, ARG2, NOS3 | THRB 2264/4885KMT2A 2858/4885MEN1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.